Printer Friendly

IMCERA'S MALLINCKRODT MEDICAL UNIT TO OPERATE MO99 PRODUCTION FACILITY AT NUCLEAR MEDICINE PLANT IN THE NETHERLANDS

 IMCERA'S MALLINCKRODT MEDICAL UNIT TO OPERATE MO99 PRODUCTION
 FACILITY AT NUCLEAR MEDICINE PLANT IN THE NETHERLANDS
 NORTHBROOK, Ill., April 6 /PRNewswire/ -- IMCERA Group Inc. (NYSE: IMA) announced today that its St. Louis-based Mallinckrodt Medical, Inc. Dutch subsidiary, Mallinckrodt Medical B.V., signed an agreement with the Netherlands Energy Research Foundation (ECN) to construct a plant in Petten, the Netherlands, dedicated to the manufacture of Molybdenum-99 (Mo99), a key raw material used in the production of the nuclear medicine imaging product, technetium-99m.
 "The radioisotope technetium-99m is essential in the practice of nuclear medicine imaging," according to William Mercer, senior vice president and group executive at Mallinckrodt Medical. "It is used in the majority of nuclear medicine procedures, including diagnostic scans of the heart, skeletal structure and other vital organs. Technetium-99m will enjoy increased utility through the discovery of new compounds and applications relating to biotechnology."
 The technology for the Mo99 production has been acquired by Mallinckrodt Medical B.V. through a license transfer from the Nuclear Research Center at Karlsruhe Germany (KfK).
 Mallinckrodt Medical supplies technetium-99m worldwide to hospital nuclear medicine departments and to the company's own network of nuclear medicine pharmacies across the U.S. and in Canada. Mallinckrodt Medical is one of the largest purchasers of Mo99 in the world, and this represents a vertical integration of the key strategic raw material.
 "The integration of a Mo99 facility in the Mallinckrodt Medical operation is part of a long-term strategy to guarantee the availability and quality of a key raw material," says Henk van Rossem, general manager of Mallinckrodt's European nuclear medicine division. "We are particularly happy to bring together the unique combination of a high-tech ECN environment, KfK's 20 years of experience in high quality material purification and a leading nuclear medicine company with global capabilities."
 The plant will be constructed at the ECN facilities adjacent to Mallinckrodt Medical's radiopharmaceutical plant in Petten. The plant will serve Mallinckrodt Medical's European and U.S. generator production facilities. Full production is scheduled to begin by the end of 1994.
 The company's radiopharmaceutical manufacturing and distribution operations in Petten, are part of a campus which also includes several government-sponsored nuclear and energy-related institutions, including the Netherlands Energy Research Foundation. A key feature of the Petten campus is the facility's high flux nuclear reactor which is operated by the ECN and well suited for producing Mo99.
 The worldwide nuclear medicine market is currently about $600 million and projected to grow at a compound annual rate of 13 percent to approximately $1.1 billion by the mid-1990s.
 Mallinckrodt Medical, with fiscal 1991 net sales and operating earnings of $513 million and $87 million, respectively, ranks as a worldwide leader in the production of radiopharmaceuticals used in nuclear medicine. The company also is a major supplier of products for radiology, cardiology, anesthesiology and critical care.
 IMCERA, a Fortune 300 company with fiscal 1991 net sales of more than $1.6 billion, has two other international, technology-based businesses -- Mallinckrodt Specialty Chemicals of Chesterfield, Mo., and Pitman-Moore of Lake Forest, Ill.
 -0- 4/6/92
 /CONTACT: Roxanne Motchan, 314-895-2078, or (investors) David Prichard, 708-205-2270, both of IMCERA/
 (IMA) CO: IMCERA Group Inc. ST: Missouri, Illinois IN: MTC SU:


TS -- NY054 -- 5366 04/06/92 12:38 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 6, 1992
Words:540
Previous Article:COMPUTER INDUSTRY FAILS TO RAISE WORKER PRODUCTIVITY; DELL COMPUTER CEO CHIDES INDUSTRY FOR IGNORING CUSTOMER NEEDS
Next Article:A MEDIA REMINDER NOTICE: EUROPEAN SKIN CARE EXECUTIVE IN LOS ANGELES; WILL PROMOTE PRODUCT AND STANDARD FOR DEFINING 'NATURAL'


Related Articles
IMCERA'S MALLINCKRODT MEDICAL UNIT ACQUIRES FRENCH MEDICAL TUBE MANUFACTURER
IMCERA'S BOARD OF DIRECTORS APPROVES $100 MILLION PROGRAM TO EXPAND MALLINCKRODT MEDICAL'S OPTIRAY PRODUCTION CAPACITY
IMCERA'S MALLINCKRODT SPECIALTY CHEMICALS UNIT AND HERCULES COMPLETE FORMATION OF FLAVORS 50/50 JOINT VENTURE
IMCERA'S MALLINCKRODT MEDICAL UNIT INTRODUCES ULTRAJECT PREFILLED SYRINGE IN GERMANY
IMCERA'S MALLINCKRODT MEDICAL ANNOUNCES $15 MILLION EXPANSION AT RALEIGH, N.C., PLANT
MALLINCKRODT MEDICAL INCREASES STAKE IN MALLINCKRODT IBERICA S.A.
IMCERA'S MALLINCKRODT MEDICAL UNIT SUBMITS NEW DRUG APPLICATION TO FDA FOR CANCER IMAGING AGENT
IMCERA'S MALLINCKRODT MEDICAL UNIT AND SANDOZ PHARMA LTD. SIGN AGREEMENT TO SHARE MOLECULAR RESEARCH
IMCERA'S MALLINCKRODT MEDICAL UNIT CLOSES AGREEMENT WITH SYNCOR TO DISTRIBUTE TECHNESCAN MAG3 RENAL IMAGING AGENT
OCTREOSCAN 111 FROM IMCERA'S MALLINCKRODT MEDICAL UNIT RECOMMENDED FOR MARKETING BY FDA MEDICAL IMAGING DRUGS ADVISORY COMMITTEE

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters